This website is currently under maintenance.

IPCOR  Update:

IPCOR finished collecting data in January 2020. We would like to thank all the men who were involved in the study and the hospital staff that facilitated the data collection. We are grateful for our research partners NCRI and the HRB-CRFG and the staff in both for making IPCOR a success. We are thankful to our funders the Irish Cancer Society and Movember for enabling the data collection and research. 

IPCOR’s host institution Clinical Research Development Ireland (CRDI) has been wound down and in March 2021 the IPCOR project moved to CRDI member institution UCD. We are excited to be developing a research program to utilise the data in the IPCOR project and start sharing the outputs.

Welcome to IPCOR, the Irish Prostate Cancer Outcomes Research

IPCOR is collecting clinical data and quality of life information from men who have been newly diagnosed with prostate cancer in Ireland and is developing, for the first time, a national prostate cancer registry. IPCOR publishes annual reports on the outcomes of prostate cancer treatment and care. These reports provide evidence-based data to doctors, hospitals and policy makers to inform future healthcare decisions that affect prostate cancer care.

The ultimate goal of IPCOR is to enhance prostate cancer care, improve patient experiences and maximise quality of life for men diagnosed with prostate cancer in Ireland.

The Irish Prostate Cancer Outcomes Research began in February 2014. The Irish Cancer Society and Movember are supporting this project with funding of €1.75 million over 5 years. This research is being carried out by a collaborative partnership involving the National Cancer Registry Ireland, the HRB Clinical Research Facility in Galway, the National Cancer Control Program and the nation’s major academic institutions represented by Clinical Research Development Ireland.

Reports and Publications

You can see our reports and publications here.

To request removal from the IPCOR dataset, please click here.